198 related articles for article (PubMed ID: 32914407)
1. Predicting malignancy in patients with adrenal tumors using
Vos EL; Grewal RK; Russo AE; Reidy-Lagunes D; Untch BR; Gavane SC; Boucai L; Geer E; Gopalan A; Chou JF; Capanu M; Strong VE
J Surg Oncol; 2020 Dec; 122(8):1821-1826. PubMed ID: 32914407
[TBL] [Abstract][Full Text] [Related]
2. Characterization of adrenocortical tumors by
Paladino NC; Guérin C; Lowery A; Attard A; Essamet W; Slotema E; Morange I; Castinetti F; Brue T; Loundou A; Taïeb D; Sebag F
Surg Oncol; 2018 Jun; 27(2):231-235. PubMed ID: 29937176
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
[TBL] [Abstract][Full Text] [Related]
4. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?
Kunikowska J; Matyskiel R; Toutounchi S; Grabowska-Derlatka L; Koperski L; Królicki L
Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2273-80. PubMed ID: 25027709
[TBL] [Abstract][Full Text] [Related]
5. Risk stratification of adrenal masses by [
Salgues B; Guerin C; Amodru V; Pattou F; Brunaud L; Lifante JC; Mirallié E; Sahakian N; Castinetti F; Loundou A; Baumstarck K; Sebag F; Taïeb D
Clin Endocrinol (Oxf); 2021 Feb; 94(2):133-140. PubMed ID: 32978795
[TBL] [Abstract][Full Text] [Related]
6. [Use of 18F-FDG-positron emission tomography in presurgical evaluation of nonspecific or suspectious adrenal masses in non-oncologic patients].
Pavón-Paz I; Rosado-Sierra JA; Balsa-Bretón MÁ; Guijarro-Armas G; Merino-Viveros M; Penín-Gonzalez FJ
Med Clin (Barc); 2016 Feb; 146(3):104-7. PubMed ID: 26343158
[TBL] [Abstract][Full Text] [Related]
7. FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours.
Nakajo M; Jinguji M; Fukukura Y; Kajiya Y; Tani A; Nakajo M; Nakabeppu Y; Arimura H; Nishio Y; Nakamura F; Yoshiura T
Eur Radiol; 2015 Dec; 25(12):3696-705. PubMed ID: 25925356
[TBL] [Abstract][Full Text] [Related]
8. Characterization of lipid-rich adrenal tumors by FDG PET/CT: Are they hormone-secreting or not?
Takanami K; Kaneta T; Morimoto R; Satoh F; Nakamura Y; Takase K; Takahashi S
Ann Nucl Med; 2014 Feb; 28(2):145-53. PubMed ID: 24272068
[TBL] [Abstract][Full Text] [Related]
9. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study.
Guerin C; Pattou F; Brunaud L; Lifante JC; Mirallié E; Haissaguerre M; Huglo D; Olivier P; Houzard C; Ansquer C; Hindié E; Loundou A; Archange C; Tabarin A; Sebag F; Baumstarck K; Taïeb D
J Clin Endocrinol Metab; 2017 Jul; 102(7):2465-2472. PubMed ID: 28431167
[TBL] [Abstract][Full Text] [Related]
10. Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands.
Koopman D; van Dalen JA; Stigt JA; Slump CH; Knollema S; Jager PL
Ann Nucl Med; 2016 Feb; 30(2):145-52. PubMed ID: 26644009
[TBL] [Abstract][Full Text] [Related]
11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of metabolic tumor volume assessed by 18F-FDG PET/CT added to SUVmax for characterization of thyroid 18F-FDG incidentaloma.
Kim BH; Kim SJ; Kim H; Jeon YK; Kim SS; Kim IJ; Kim YK
Nucl Med Commun; 2013 Sep; 34(9):868-76. PubMed ID: 23797273
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic performance of
Altinmakas E; Hobbs BP; Ye H; Grubbs EG; Perrier ND; Prieto VG; Lee JE; Ng CS
Abdom Radiol (NY); 2017 Feb; 42(2):577-584. PubMed ID: 27665482
[TBL] [Abstract][Full Text] [Related]
14. The correlation of
Qu YH; Long N; Ran C; Sun J
Clin Transl Oncol; 2021 Mar; 23(3):620-627. PubMed ID: 32683540
[TBL] [Abstract][Full Text] [Related]
15. High False Positivity in Positron Emission Tomography is a Potential Diagnostic Pitfall in Patients with Suspected Adrenal Metastasis.
Lang BH; Cowling BJ; Li JY; Wong KP; Wan KY
World J Surg; 2015 Aug; 39(8):1902-8. PubMed ID: 25809060
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic performances of FDG-PET/CT and diffusion-weighted imaging indices for differentiating benign pheochromocytoma from other benign adrenal tumors.
Nakajo M; Nakajo M; Fukukura Y; Jinguji M; Shindo T; Nakabeppu Y; Kamimura K; Yoneyama T; Takumi K; Yoshiura T
Abdom Imaging; 2015 Aug; 40(6):1655-65. PubMed ID: 25382022
[TBL] [Abstract][Full Text] [Related]
17. Prediction of ultrasound guided fine needle aspiration cytology results by FDG PET-CT for lymph node metastases in head and neck squamous cell carcinoma patients.
Peltenburg B; de Keizer B; Dankbaar JW; de Boer M; Willems SM; Philippens MEP; Terhaard CHJ; de Bree R
Acta Oncol; 2018 Dec; 57(12):1687-1692. PubMed ID: 30489180
[TBL] [Abstract][Full Text] [Related]
18. Total lesion glycolysis as the best 18F-FDG PET/CT parameter in differentiating intermediate-high risk adrenal incidentaloma.
Kim YI; Cheon GJ; Paeng JC; Cho JY; Kang KW; Chung JK; Kim EE; Lee DS
Nucl Med Commun; 2014 Jun; 35(6):606-12. PubMed ID: 24598843
[TBL] [Abstract][Full Text] [Related]
19. Adrenal-to-liver SUV ratio is the best parameter for differentiation of adrenal metastases from adenomas using 18F-FDG PET/CT.
Watanabe H; Kanematsu M; Goshima S; Kondo H; Kawada H; Noda Y; Moriyama N
Ann Nucl Med; 2013 Aug; 27(7):648-53. PubMed ID: 23625579
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of F-18 FDG PET/CT with optimal cut-offs of maximum standardized uptake value according to size for diagnosis of regional lymph node metastasis in patients with rectal cancer.
Bae SU; Won KS; Song BI; Jeong WK; Baek SK; Kim HW
Cancer Imaging; 2018 Sep; 18(1):32. PubMed ID: 30217167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]